Core Insights - The pharmaceutical industry presents attractive passive income opportunities for investors, particularly through dividend-paying stocks like Pfizer and AbbVie, which have raised their payouts despite stock price underperformance [1][2] Pfizer - Pfizer's stock has lost approximately 50% of its value since the end of 2022, yet it has increased its quarterly dividend for the 15th consecutive year [3][4] - The current dividend yield for Pfizer stands at 6.5%, with expectations for further increases in the future [4] - Sales of cancer therapies surged by 31% year-over-year, driven by strong performance from the prostate cancer drug Xtandi and the combination therapy with Talzenna [5][7] - Pfizer's acquisition of Biohaven and its migraine drug Nurtec positions it favorably in the market, with 85% of primary care clinicians prescribing Nurtec [6][7] - The company anticipates adjusted earnings of $2.85 per share this year, supporting its annualized dividend payout of $1.68 per share [7] AbbVie - AbbVie's stock has only increased by 9.5% since the end of 2022, primarily due to the loss of patent protection for its leading drug, Humira, which saw sales drop from $21.2 billion in 2022 to an annualized $8.9 billion in Q3 2023 [8][9] - Despite the decline in Humira sales, AbbVie is raising its dividend payout by 5.8% for February, resulting in a current yield of 3.7% [9] - Third-quarter sales of Humira fell by 37% year-over-year, but this was offset by strong sales from newer drugs Skyrizi and Rinvoq, which together generated $19.3 billion in annualized sales [10] - The FDA's approval of Vyalev, a new Parkinson's disease treatment, adds to AbbVie's growth potential, targeting a significant patient population [11] - AbbVie has increased its dividend more than fourfold since its spin-off from Abbott Laboratories in 2013, indicating a strong outlook for continued dividend growth [12]

AbbVie (NYSE: ABBV ) is a biopharma company, made famous by its blockbuster Humira, at one point the best-selling drug in the world. As biosimilars have eroded Humira ABBV has gone on an acquisition spree to replace lost Humira revenuesBuildingBenjamins is a free stock picking and market commentary investment newsletter. Building Benjamins is the DBA (doing businesses as) publishing entity for Tradition Investment Management, LLC, a registered investment adviser. Benjamin Halliburton, our founder, also foun ...

AbbVie’s (ABBV) shares rose 3.0% on Friday after Leerink Partners analyst, David Risinger, upgraded his rating on the stock from Market Perform to Outperform.Excluding Friday’s movement, AbbVie stock fell almost 19% in November, mainly due to the failure oftwo registration-enabling phase II studies on emraclidine, its once-daily oral candidate for treating schizophrenia. Earlier this month, AbbVie announced that the studies failed to meet their primary endpoints. Emraclidine was added to AbbVie’s pipeline w ...

Group 1 - The report titled "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" provides insights into AbbVie's technology activities, including digital transformation strategies and innovation programs [1][2] - AbbVie is a diversified research-based biopharmaceutical company focused on developing, manufacturing, marketing, and selling medicines for serious and complex diseases [3] - The company's product portfolio includes immunology, oncology, aesthetics, neuroscience, and eye care products [3][4] Group 2 - AbbVie's immunology products include Humira, Skyrizi, and Rinvoq, while its oncology products feature Imbruvica, Venclexta, Epkinly, and Elahere [4] - The aesthetics product portfolio consists of Botox Cosmetic, the Juvederm Collection of Fillers, Alloderm regenerative dermal tissue, and Latisse eyelash solution [4] - AbbVie also manufactures medicines for hepatitis C virus infection, metabolic and hormonal diseases, and endocrinology diseases [5] Group 3 - The report outlines key topics such as digital transformation strategy, innovation programs, technology initiatives, partnerships, ICT budget, and major contracts [5] - Insights into AbbVie's technology themes, objectives, and benefits of various initiatives are included [2][5] - The report aims to provide a comprehensive understanding of AbbVie's tech operations and strategies [5]

NORTH CHICAGO, Ill., Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., executive vice president, Research & Development and chief scientific officer, will present at 9:15 a.m. Central time.A live audio webcast of the presentation will be accessible through ...

Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in the index is trading at more than 25 times earnings. However, there are still many deals out there. Two stocks that could be among the best bargains right now include AbbVie (ABBV 3.04%) Comcast (CMCSA -0.07%)AbbVieDrugmaker AbbVie isn't having a great year, but it's not having a bad one, either. Its year-to-da ...

Core Viewpoint - Political uncertainty has created buying opportunities among blue-chip healthcare stocks with significant dividends, particularly due to the nomination of Robert F. Kennedy Jr. as Secretary of Health and Human Services, which has introduced volatility in the healthcare sector [1][2]. Group 1: AbbVie - AbbVie shares are down over 18% from their high, influenced by political factors and the $8.7 billion acquisition of Cerevel, which faced setbacks with its schizophrenia drug emraclidine failing clinical trials [3][4]. - Despite the challenges, AbbVie remains a well-diversified company with a solid dividend yield of 3.7% and a payout ratio of 56% of estimated 2024 earnings, indicating financial stability [4][5]. - The stock trades at a forward P/E ratio of 15, with analysts projecting earnings growth of 8% to 9% annually, presenting an opportunity for investors to achieve total returns averaging 11% to 13% annually [5]. Group 2: Pfizer - Pfizer's stock has been negatively impacted by declining earnings and industry sentiment, trading at less than 9 times earnings, with a dividend yield of 6.7%, the highest since the financial crisis [6][7]. - The company's dividend payout ratio is only 58% of its 2024 earnings estimates, and Pfizer is shifting focus to oncology, with expected earnings growth of 10% to 11% annually over the next three to five years [7][8]. - Pfizer presents a high-yield dividend stock at a bargain price, with management committed to supporting and increasing the dividend, making it a contrarian investment opportunity [8]. Group 3: Johnson & Johnson - Johnson & Johnson's stock has declined 18% from its high, trading at 15 times 2024 earnings estimates, amid ongoing talcum powder litigation that could incur significant costs [9][10]. - The company maintains strong fundamentals with over $20 billion in cash, and any settlements are expected to be paid over many years, indicating resilience [10][11]. - Analysts forecast earnings growth of 5% to 6% annually, with a modest 50% payout ratio based on 2024 earnings estimates, providing a generous 3.2% yield and a growing dividend [11].

As I was researching this article about AbbVie (NYSE: ABBV ), its price fell 16.8% due to negative data from two Phase 2 clinical trials evaluating the efficacy of emraclidine in treating schizophrenia. The stock fell in five consecutive sessions beforeWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs ...

Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (ABBV -1.23%) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit.Here's where this company will be going, and where it's probably going to end up.It's hard to see this business getting any smallerIn the next five years, expect AbbVie to continue to compete in the disease areas t ...

AbbVie (ABBV) announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.Following the approval, Elahere became the first and only FRα-directe ...